z-logo
Premium
Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma
Author(s) -
Takahashi Shigeo,
Kimura Tomoki,
Kenjo Masahiro,
Nishibuchi Ikuno,
Takahashi Ippei,
Takeuchi Yuki,
Doi Yoshiko,
Kaneyasu Yuko,
Murakami Yuji,
Honda Yoji,
Aikata Hiroshi,
Chayama Kazuaki,
Nagata Yasushi
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12241
Subject(s) - medicine , portal vein thrombosis , hepatocellular carcinoma , radiology , stenosis , thrombosis , bile duct , portal vein
The aim of this study was to evaluate portal vein and bile duct toxicity after stereotactic body radiation therapy ( SBRT ) for hepatocellular carcinoma ( HCC ). We retrospectively reviewed 63 patients who were administrated SBRT once for HCC . The prescribed doses were from 48 Gy in four fractions to 60 Gy in eight fractions. Portal vein thrombosis and bile duct stenosis were evaluated. The dose received by 2% of the volume ( D 2 ) of the portal vein and bile duct was calculated. Portal vein thrombosis was observed in three patients (4.8%). Common points of these patients were C hild– P ugh class B and D 2 of the portal vein 40 Gy or more ( BED 3 ≥200 Gy). Bile duct stenosis was observed in one patient (1.6%). The patient had a history of cholangiocarcinoma and left hepatic lobectomy. Portal vein thrombosis may be necessary to be considered when SBRT for HCC is administrated to patients in higher C hild– P ugh class with higher D 2 of the portal vein.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom